Latest Information Update: 30 Jul 2002
At a glance
- Originator Eli Lilly
- Class Obesity therapies; Propylamines; Small molecules
- Mechanism of Action Adrenergic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 15 Jun 1999 Preclinical development for Obesity in USA (PO)